Monoclonal Antibody 9C4 Recognizes Epithelial Cellular Adhesion Molecule, a Cell Surface Antigen Expressed in Early Steps of Erythropoiesis
Overview
Authors
Affiliations
Objective: Monoclonal antibody (mAb) 9C4 detects a surface antigen expressed on immature erythroid progenitor cells and epithelial tumor cell lines. The aim of this study was to identify the recognized surface antigen and to analyze a potential role of this molecule in early steps of erythropoiesis.
Materials And Methods: A pituitary-derived retroviral cDNA library was used to generate viruses and infect NIH-3T3 fibroblasts. The transfected cells were stained with mAb 9C4; positive cells were sorted by FACS; and a clonal cell line binding mAb 9C4 was established. cDNA encoding the 9C4-binding protein was amplified by polymerase chain reaction and cloned. Reactivity of mAb 9C4 with human bone marrow (BM) cells was analyzed by flow cytometry.
Results: Sequence analysis of the isolated cDNA uncovered a 100% identity with the epithelial cellular adhesion molecule (Ep-CAM). Two-color flow cytometric analysis revealed that almost 100% of Ep-CAM(+) BM cells coexpressed CD105, E-cadherin, and high levels of CD71. Fractions of Ep-CAM(+) BM cells also were CD34(+) but lacked glycophorin A expression, suggesting that Ep-CAM(+) cells represent immature erythroid cells. Reverse transcriptase polymerase chain reaction analysis of BM mononuclear cells revealed that the 9C4(+) erythroblast population but not the 9C4(-) fraction expressed Ep-CAM mRNA. Peripheral blood CD34(+) cells induced in vitro to differentiate into the erythroid lineage showed strong Ep-CAM expression on days 3 to 7 of culture. The addition of Ep-CAM-specific mAbs 9C4 or KS1/4 to the culture resulted in two- to three-fold up-regulation of Ep-CAM protein expression.
Conclusion: mAb 9C4 recognizes Ep-CAM, a molecule expressed in the early steps of erythropoiesis.
Fidanza A, Stumpf P, Ramachandran P, Tamagno S, Babtie A, Lopez-Yrigoyen M Blood. 2020; 136(25):2893-2904.
PMID: 32614947 PMC: 7862875. DOI: 10.1182/blood.2020006229.
Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.
van der Toom E, Axelrod H, de la Rosette J, de Reijke T, Pienta K, Valkenburg K Nat Rev Urol. 2018; 16(1):7-22.
PMID: 30479377 PMC: 6324967. DOI: 10.1038/s41585-018-0119-5.
Chalfin H, Glavaris S, Malihi P, Sperger J, Gorin M, Lu C J Urol. 2018; 199(6):1494-1501.
PMID: 29339080 PMC: 5964005. DOI: 10.1016/j.juro.2018.01.033.
Circulating and disseminated tumor cells: harbingers or initiators of metastasis?.
Dasgupta A, Lim A, Ghajar C Mol Oncol. 2017; 11(1):40-61.
PMID: 28085223 PMC: 5423226. DOI: 10.1002/1878-0261.12022.
The biology and clinical implications of prostate cancer dormancy and metastasis.
Morrissey C, Vessella R, Lange P, Lam H J Mol Med (Berl). 2015; 94(3):259-65.
PMID: 26489605 PMC: 4803572. DOI: 10.1007/s00109-015-1353-4.